Showing results (51-60 of 101) with videos related to
Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categoriesJan J Cornelissen, Dimitri Breems, Wim L J van Putten, et al.The New England Journal of Medicine|March 18, 2011
Cytarabine dose for acute myeloid leukemiaBob Löwenberg, Thomas Pabst, Edo Vellenga, et al.Leukemia Research|August 4, 2004
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adultsSimon Daenen, Bronno van der Holt, Gregor E G Verhoef, et al.Blood|January 11, 2007
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Jan J Cornelissen, Wim L J van Putten, Leo F Verdonck, et al.Blood|July 2, 2002
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapseStephanie J Lee, John P Klein, A John Barrett, et al.Blood|April 9, 2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patientsGert J Ossenkoppele, Wilfried J Graveland, Pieter Sonneveld, et al.The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalitiesStefan Gröschel, Sanne Lugthart, Richard F Schlenk, et al.Blood|January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBob Löwenberg, Joachim Beck, Carlos Graux, et al.International Journal of Radiation Oncology, Biology, Physics|February 26, 2008
Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centersM Loes van Kempen-Harteveld, Ronald Brand, Henk B Kal, et al.Pageof 11